{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:51:19Z","timestamp":1761094279361,"version":"build-2065373602"},"reference-count":119,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Hematopoietic cell transplantation (HCT) is an essential component of potentially curative therapy for patients with hematologic malignancies. High\u2010dose chemotherapy with autologous (auto) stem cell rescue is used to overcome chemoresistance in multiple myeloma, non\u2010Hodgkin lymphoma, and Hodgkin lymphoma. Alternatively, poor\u2010risk acute leukemias rely on the graft versus leukemia effect of allogeneic (allo) products. Long\u2010term remissions are feasible with both auto\u2010 and allo\u2010HCT; however, disease relapse is the leading cause of death after HCT for many patients. In recognition of this, novel therapies are being investigated in the upfront, relapsed\/refractory, and post\u2010HCT maintenance settings to deepen response and maintain disease control. To date, the most robust data to support this approach are in multiple myeloma, where post\u2010transplant maintenance therapy has improved clinical outcomes. In Hodgkin lymphoma, patients with high\u2010risk features may benefit from post\u2013auto\u2010HCT vedotin (BV) regardless of pre\u2010HCT BV exposure. Apart from mantle cell lymphoma, where rituximab maintenance is generally accepted, post\u2013auto\u2010HCT maintenance in other forms of NHL is less established. In patients who undergo allo\u2010HCT, the utilization of maintenance therapy is an important component of improving post\u2010HCT outcomes, however, an individualized approach that considers patient factors such as residual toxicity from HCT, an immature graft with poor graft function, infection, and graft\u2010versus\u2010host disease create a complex environment for aggressive interventions. Initiation of directed agents in patients with identified mutations prior to allo\u2010HCT, including FLT3 in acute myeloid leukemia and Philadelphia chromosome in acute lymphoid leukemia have generally improved post\u2010HCT outcomes. Ongoing studies are exploring the safety and efficacy of additional maintenance strategies post\u2013allo\u2010HCT in an effort to further improve post\u2010HCT outcomes.<\/jats:p>","DOI":"10.1002\/phar.2407","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T08:56:07Z","timestamp":1588064167000},"page":"727-740","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Maintenance Strategies After Hematopoietic Cell Transplantation"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-0859","authenticated-orcid":false,"given":"Kathryn A.","family":"Culos","sequence":"first","affiliation":[{"name":"Department of Pharmacy Vanderbilt University Medical Center Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie S.","family":"Gatwood","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Vanderbilt University Medical Center Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"National Comprehensive Cancer Network.B\u2010Cell Lymphomas (Version 7.2019). Available fromhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b\u2010cell.pdf. Accessed December 17 2019."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.035"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.6"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718786437"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00551-7"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0205-9"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06405.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6081"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.83"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222539"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-451872"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30140-0"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.35"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.002"},{"key":"e_1_2_6_31_1","unstructured":"Network NCC.Multiple Myeloma (Version 2.2020). Available fromhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed December 17 2019."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12582"},{"key":"e_1_2_6_33_1","unstructured":"Network NCC.Hodgkin Lymphoma (Version 2.2019). Available fromhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf. Accessed December 15 2019."},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.177"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx072"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282756"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238799"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6278"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701742506"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol_00000128"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0055-7"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1862"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2705-z"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254441"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0259"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-385781"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.024"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.007"},{"key":"e_1_2_6_58_1","first-page":"94","article-title":"Salvage therapy after allogeneic hematopoietic cell transplantation: targeted and low\u2010intensity treatment options in myelodysplastic syndrome and acute myeloid leukemia","volume":"2","author":"Culos K","year":"2019","journal-title":"Clin Hematol Int"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12948"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"e_1_2_6_63_1","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low\u2010dose decitabine versus best supportive care in elderly patients with intermediate\u2010 or high\u2010risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"15","author":"L\u00fcbbert M","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25500"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111582"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1443334"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.739"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128316"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123402"},{"key":"e_1_2_6_71_1","article-title":"Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high risk acute myeloid leukemia","author":"Tang X","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04500.x"},{"key":"e_1_2_6_73_1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"6","author":"Kottaridis PD","year":"2001","journal-title":"Blood"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.09.007"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30680"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112614"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127594"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.12.005"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14260"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0493-5"},{"issue":"1","key":"e_1_2_6_81_1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2019-124504","article-title":"Clinical outcomes and characteristics of patients (pts) with FLT3\u2010Internal Tandem Duplication (FLT3\u2010ITD)\u2010mutated Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML) undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum\u2010R trial","volume":"134","author":"Ganguly S","year":"2019","journal-title":"Blood"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.077"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116342"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.502"},{"key":"e_1_2_6_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.404"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.11.1517"},{"key":"e_1_2_6_97_1","first-page":"23","article-title":"Topics in pediatric leukemia\u2013acute lymphoblastic leukemia","volume":"1","author":"Esparza SD","year":"2005","journal-title":"Med Gen Med"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149286"},{"key":"e_1_2_6_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0099-z"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_2_6_102_1","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome\u2010positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"19","author":"Giebel S","year":"2016","journal-title":"Cancer"},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.022"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.352"},{"key":"e_1_2_6_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-29"},{"key":"e_1_2_6_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1746"},{"key":"e_1_2_6_107_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.040261"},{"key":"e_1_2_6_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14167"},{"key":"e_1_2_6_109_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13439"},{"key":"e_1_2_6_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29141"},{"key":"e_1_2_6_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.12.587"},{"key":"e_1_2_6_112_1","first-page":"301","article-title":"High efficacy of dasatinib in maintenance therapy after allogeneic haematopoietic stem cell transplantation in patients with Philadelphia chromosome\u2010positive acute lymphoblastic leukemia","volume":"51","author":"Czyz A","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.201"},{"key":"e_1_2_6_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07185.x"},{"key":"e_1_2_6_115_1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","article-title":"Hematopoietic stem cell transplantation for adults with Philadelphia chromosome\u2010negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"6","author":"Giebel S","year":"2019","journal-title":"Bone Marrow Transplant"},{"volume-title":"Besponsa (inotuzumab ozogamicin) [prescribing information]","year":"2018","author":"Wyeth Pharmaceuticals Inc","key":"e_1_2_6_116_1"},{"key":"e_1_2_6_117_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"volume-title":"Blincyto (blinatumomab) [precribing information]","year":"2019","author":"Amgen Inc","key":"e_1_2_6_118_1"},{"key":"e_1_2_6_119_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S149420"},{"key":"e_1_2_6_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125931"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:50Z","timestamp":1761059330000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/phar.2407"],"URL":"https:\/\/doi.org\/10.1002\/phar.2407","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"2020-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}